Clinical Trial Links Daily Tomato Consumption to Reduced Liver Fat in MASLD Patients
A recent clinical trial has highlighted the potential benefits of daily tomato consumption in reducing liver fat among adults diagnosed with metabolic dysfunction-associated steatotic liver disease (MASLD). This condition is characterized by the accumulation of fat in the liver, often accompanied by cardiometabolic risk factors such as obesity or high blood pressure. The rise in cases of metabolic liver disease has been alarming, with estimates suggesting that 1.3 billion people were affected globally in 2023, marking a 143% increase since 1990. Furthermore, MASLD has been identified as the fastest-growing cause of liver cancer.
In this six-week randomized controlled trial, participants were selected based on specific criteria, excluding those who consumed excessive alcohol, had a body mass index (BMI) over 30, or were older than 65. The majority of the participants were men, and they were instructed to maintain their usual routines aside from incorporating tomato products from a single producer into their diets. Researchers measured various health indicators, including body composition, liver fat levels, liver stiffness, and cholesterol levels.
The results indicated a decline in hepatic steatosis in both the tomato group and the control group, but the reduction was significantly greater in those consuming tomatoes. Notably, the study found no major differences in liver stiffness, lipid levels, liver enzymes, or BMI between the two groups post-intervention. The authors of the study suggested that the consumption of tomatoes may help reduce liver fat accumulation without necessitating significant changes in body weight or overall adiposity.
The increasing prevalence of fatty liver disease correlates with rising rates of metabolic syndrome, obesity, and sedentary lifestyles. However, the study did not measure the levels of lycopene or carotenoids—compounds in tomatoes thought to contribute to liver health. Experts not involved in the study have urged caution in interpreting these findings. Dr. Randa Abdelmasih, an endocrinologist, noted that the results reflect a modest reduction in liver fat over a short duration in a highly selected population, raising questions about the generalizability of the findings to the broader patient population, which often presents with multiple risk factors.
Additionally, Dr. Jonathan Jennings emphasized the importance of recognizing that not all cardiometabolic risk factors carry equal weight. He pointed out that individuals with type 2 diabetes are at a higher risk for developing MASLD compared to those with high blood pressure, yet the study treated these factors as equivalent.
The authors acknowledged several limitations, including the short duration of the trial and the combined use of raw tomatoes and tomato sauce. They also highlighted that while improvements in liver fat were observed, there were no significant changes in liver stiffness, fibrosis scores, or other metabolic markers. Therefore, while the findings are intriguing, they do not establish that tomato consumption can meaningfully alter disease progression or improve clinically relevant outcomes.
The trial is described as exploratory and hypothesis-generating, with the authors calling for further research to confirm these findings over longer periods and to identify which components of tomatoes may be responsible for the observed effects. Experts agree that dietary changes should be considered as part of a comprehensive approach to managing metabolic health, with sustained weight loss remaining the most evidence-backed intervention for improving liver health in patients with obesity and metabolic disease. Overall, while the study offers preliminary evidence that tomatoes may play a role in reducing liver fat, it is essential to view these results within the broader context of metabolic health management.




